Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Decreased immunoreactivity of platelet-derived growth factor B chain-like peptide after axotomy in the dorsal motor nucleus of the vagus nerve.

Authors: Yamada, E  Hazama, F 
Citation: Yamada E and Hazama F, Brain Res. 1994 Jul 18;651(1-2):108-14.
Pubmed: (View Article at PubMed) PMID:7922556

Platelet-derived growth factor-B chain (PDGF-B) and B chain-specific beta receptor (PDGF-R) were investigated immunohistochemically in the dorsal motor nucleus of the vagus nerve and hypoglossal nucleus after axotomy using antibodies raised against synthetic polypeptides. PDGF-B and PDGF-R immunoreactivity were observed in nerve cell bodies contralateral to the axotomized nerve in both vagal (degenerative) and hypoglossal (regenerative) nuclei. The immunoreactivity for PDGF-B antibody persisted until day 28 after axotomy in the hypoglossal neurons, while that in many neurons in the vagal nucleus diminished after day 3. In the severed vagal nucleus some of the axotomized neurons showed no immunoreactivity for PDGF-B chain, and these changes preceded the decrease in neuronal numbers in the vagal nucleus. The immunoreactivity for PDGF-R antibody showed no marked change in either the vagal or hypoglossal nucleus until day 28 after axotomy. These findings suggest that the decrease in PDGF-B immunoreactivity is not due to a non-specific depletion of cytoplasmic protein in the severed vagal neurons. PDGF, taken up by the nucleus and bound to chromatin, has been reported to exert direct effects on the enhancement of transcription and synthesis of RNA. The decrease in level of PDGF-B chain in the vagal neurons seems to cause the reduction of RNA and protein synthesis, resulting in neuronal degeneration.

Annotation

Gene Ontology Annotations
Objects Annotated

Additional Information

 
CRRD Object Information
CRRD ID: 10449483
Created: 2016-01-06
Species: All species
Last Modified: 2016-01-06
Status: ACTIVE



NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.